LOCHMANOVÁ, Jana, Boris TICHÝ, Karla PLEVOVÁ, Petr DOBEŠ, Veronika NAVRKALOVÁ, Jitka MALČÍKOVÁ, Ludmila ROČŇOVÁ, Marek MRÁZ, Jaroslav ZELENÝ, Barbora DVOŘÁKOVÁ, Jiří MAYER, Martin TRBUŠEK and Šárka POSPÍŠILOVÁ. CLL-specific resequencing microarray as a tool for CLL research and diagnostics. In 1st International Conference on Advances in Cell and Gene Therapy and Immunotherapy: from basic research to clinical applications and 3rd Workshop on Immunotherapy, Mikulov. 2010.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name CLL-specific resequencing microarray as a tool for CLL research and diagnostics
Authors LOCHMANOVÁ, Jana, Boris TICHÝ, Karla PLEVOVÁ, Petr DOBEŠ, Veronika NAVRKALOVÁ, Jitka MALČÍKOVÁ, Ludmila ROČŇOVÁ, Marek MRÁZ, Jaroslav ZELENÝ, Barbora DVOŘÁKOVÁ, Jiří MAYER, Martin TRBUŠEK and Šárka POSPÍŠILOVÁ.
Edition 1st International Conference on Advances in Cell and Gene Therapy and Immunotherapy: from basic research to clinical applications and 3rd Workshop on Immunotherapy, Mikulov, 2010.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Medicine
UT WoS 000279051300098
Changed by Changed by: RNDr. Jitka Malčíková, Ph.D., učo 14364. Changed: 1/11/2010 10:09.
Links
FR-TI2/254, research and development projectName: *Real-time PCR soupravy pro diagnostiku v onkologii (Acronym: ONKOKITY)
Investor: Ministry of Industry and Trade of the CR
MSM0021622430, plan (intention)Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie
Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies
MUNI/A/1012/2009, interní kód MUName: Optimalizace diagnostiky a terapie maligních chorob a komplikací, které tyto maligní nemoci provázejí, s využitím nových molekulárně biologických metod.
Investor: Masaryk University, Category A
PrintDisplayed: 24/7/2024 23:14